Applied Immune Sciences Inc. said Tuesday it has received a$50,000 Phase I SBIR grant from the National Institutes ofHealth.
The Menlo Park, Calif., company (NASDAQ:AISX) is conducting genetherapy research that could help provide a treatment for suchdisroders as hemophilia, sickle cell anemia and ADA enzymedeficiency. The company said it is investigating the human adeno-associated virus (AAV), which has the ability to enter humancells without causing disease while carrying with it the genesneeded to correct genetic disorders.
(c) 1997 American Health Consultants. All rights reserved.